SG11201903064SA - Arsenic compositions - Google Patents
Arsenic compositionsInfo
- Publication number
- SG11201903064SA SG11201903064SA SG11201903064SA SG11201903064SA SG11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- courallie
- english
- pct
- arsenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016904945A AU2016904945A0 (en) | 2016-12-01 | Arsenic compositions | |
| PCT/AU2017/050807 WO2018098519A1 (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903064SA true SG11201903064SA (en) | 2019-05-30 |
Family
ID=62240940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903064SA SG11201903064SA (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11241453B2 (ja) |
| EP (1) | EP3548044B1 (ja) |
| JP (2) | JP7080230B2 (ja) |
| KR (1) | KR102487884B1 (ja) |
| CN (1) | CN109952105A (ja) |
| AU (1) | AU2017368444B9 (ja) |
| BR (1) | BR112019007498A2 (ja) |
| CA (1) | CA3041357A1 (ja) |
| CL (1) | CL2019001422A1 (ja) |
| DK (1) | DK3548044T3 (ja) |
| ES (1) | ES2964979T3 (ja) |
| IL (1) | IL265986B (ja) |
| MX (1) | MX2019006107A (ja) |
| NZ (1) | NZ752214A (ja) |
| PE (1) | PE20191544A1 (ja) |
| PL (1) | PL3548044T3 (ja) |
| SG (1) | SG11201903064SA (ja) |
| TW (1) | TWI808060B (ja) |
| WO (1) | WO2018098519A1 (ja) |
| ZA (1) | ZA201902156B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20190310A1 (es) | 2016-08-01 | 2019-03-01 | Veolia Water Solutions And Tech Support | Proceso para eliminar silice del agua producida y otras corrientes de aguas residuales |
| IL265986B (en) * | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | A drug compound that includes an alkali metal and/or an alkaline metal oxide tetraoxide (iii) and its uses |
| WO2022180582A1 (en) * | 2021-02-26 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Oral pharmaceutical composition of arsenic trioxide |
| JP2022151442A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 白血病治療薬。 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080004A (en) * | 1933-05-17 | 1937-05-11 | Frederick E Dearborn | Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same |
| US3280046A (en) | 1963-03-27 | 1966-10-18 | Dow Chemical Co | Polyol ether resins and utility |
| ES2309258T3 (es) | 1997-10-15 | 2008-12-16 | Polarx Biopharmaceuticals, Inc. | Composiciones farmaceuticas que comprenden trioxido de arsenico para el tratamiento de linfoma no hodgkin. |
| US6770304B2 (en) | 1997-11-10 | 2004-08-03 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN105435228B (zh) * | 2014-08-14 | 2020-08-07 | 中国科学院上海营养与健康研究所 | 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂 |
| CN107206022B (zh) * | 2015-01-29 | 2020-10-16 | 益友制药私人有限公司 | 含砷的组合物及其在治疗方法中的用途 |
| NZ734201A (en) * | 2015-02-01 | 2024-03-22 | Syros Pharmaceuticals Inc | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| IL265986B (en) * | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | A drug compound that includes an alkali metal and/or an alkaline metal oxide tetraoxide (iii) and its uses |
-
2017
- 2017-08-02 IL IL265986A patent/IL265986B/en unknown
- 2017-08-02 PE PE2019000939A patent/PE20191544A1/es unknown
- 2017-08-02 TW TW106126050A patent/TWI808060B/zh active
- 2017-08-02 PL PL17876251.4T patent/PL3548044T3/pl unknown
- 2017-08-02 JP JP2019524985A patent/JP7080230B2/ja active Active
- 2017-08-02 MX MX2019006107A patent/MX2019006107A/es unknown
- 2017-08-02 BR BR112019007498A patent/BR112019007498A2/pt active Search and Examination
- 2017-08-02 EP EP17876251.4A patent/EP3548044B1/en active Active
- 2017-08-02 CN CN201780069613.2A patent/CN109952105A/zh active Pending
- 2017-08-02 AU AU2017368444A patent/AU2017368444B9/en active Active
- 2017-08-02 KR KR1020197013881A patent/KR102487884B1/ko active IP Right Grant
- 2017-08-02 CA CA3041357A patent/CA3041357A1/en active Pending
- 2017-08-02 NZ NZ752214A patent/NZ752214A/en unknown
- 2017-08-02 ES ES17876251T patent/ES2964979T3/es active Active
- 2017-08-02 SG SG11201903064SA patent/SG11201903064SA/en unknown
- 2017-08-02 US US16/465,693 patent/US11241453B2/en active Active
- 2017-08-02 DK DK17876251.4T patent/DK3548044T3/da active
- 2017-08-02 WO PCT/AU2017/050807 patent/WO2018098519A1/en unknown
-
2019
- 2019-04-05 ZA ZA2019/02156A patent/ZA201902156B/en unknown
- 2019-05-27 CL CL2019001422A patent/CL2019001422A1/es unknown
-
2022
- 2022-02-25 JP JP2022028046A patent/JP7419415B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2964979T3 (es) | 2024-04-10 |
| PE20191544A1 (es) | 2019-10-24 |
| AU2017368444B9 (en) | 2020-07-02 |
| CN109952105A (zh) | 2019-06-28 |
| AU2017368444A1 (en) | 2019-04-18 |
| AU2017368444B2 (en) | 2020-04-30 |
| KR102487884B1 (ko) | 2023-01-11 |
| NZ752214A (en) | 2022-11-25 |
| MX2019006107A (es) | 2019-08-21 |
| KR20190089865A (ko) | 2019-07-31 |
| IL265986A (en) | 2019-06-30 |
| US11241453B2 (en) | 2022-02-08 |
| CA3041357A1 (en) | 2018-06-07 |
| EP3548044B1 (en) | 2023-09-20 |
| CL2019001422A1 (es) | 2019-08-02 |
| PL3548044T3 (pl) | 2024-03-04 |
| US20200016196A1 (en) | 2020-01-16 |
| WO2018098519A1 (en) | 2018-06-07 |
| TWI808060B (zh) | 2023-07-11 |
| DK3548044T3 (en) | 2023-12-11 |
| EP3548044A4 (en) | 2020-07-22 |
| JP7080230B2 (ja) | 2022-06-03 |
| BR112019007498A2 (pt) | 2019-07-02 |
| JP2020500845A (ja) | 2020-01-16 |
| EP3548044A1 (en) | 2019-10-09 |
| IL265986B (en) | 2022-09-01 |
| JP7419415B2 (ja) | 2024-01-22 |
| JP2022069485A (ja) | 2022-05-11 |
| ZA201902156B (en) | 2021-01-27 |
| TW201821087A (zh) | 2018-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201903064SA (en) | Arsenic compositions | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate |